Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-03-20
1997-05-20
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514317, 514330, 514535, 514540, 514626, 514826, 514914, A61K 3147, A61K 3124, A61K 3116
Patent
active
056312679
ABSTRACT:
A therapeutic method is provided to treat eosinophil-associated hypersensitivity diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4466973 (1984-08-01), Rennie
patent: 4626530 (1986-12-01), Schulte
patent: 4748022 (1988-05-01), Busciglio
patent: 5134166 (1992-07-01), Bernstein
G.H. Ayers et al., "Injurious Effect of the Eosinophil Peroxide-Hydrogen Peroxide-Halide System and Major Basic Protein on Human Nasal Epithelium in vitro", Am. Rev. Resp. Dis., 140:125 (1989).
P.J. Barnes, The Lancet, 242 (Feb. 1, 1986).
R. Bascom et al., "Major Basic Protein and Eosinophil-Derived Neurotoxin Concentrations in Nasal-Lavage Fluid After Antigen Challenge: Effect of Systemic Corticosteroids and Relationship to Eosinophil Influx", J. Allergy Clin. Immunol., 84:338 (1989).
J.H. Butterfield et al., "Chapter 8: Anti-Inflammatory Effects of Glucocorticoids on Eosinophils and Neutrophils", Anti-Inflammatory Steroid Action: Basic and Clinical Aspects, Schleimer et al., editors, Academic Press Inc., at pages 151-198 (1980).
W.Y. Chen et al., "Effects of Inhaled Lidocaine on Exercise-Induced Asthma", Respiration, 51, pp. 91-97, (1987).
H. Downes et al., "Lidocaine Aersols Do Not Prevent Allergic Bronchoconstriction", Anesth. Analg., 60, pp. 28-32, (1981).
M.S. Dunnill, "The Pathology of Asthma, with Special Reference to Changes in the Bronchial Mucosa", J. Clin. Path., 13:27 (1960).
A.G. Ellis et al., "The Pathological Anatomy of Bronchial Asthma", J. Med. Sci., 136:407 (1980).
P.L. Enright et al., Am. Rev. Resp. Disease, 172, 823 (1980).
W. Filley et al., "Identification by Immunofluorescence of Eosinophil Granule Major Basic Protein in Lung Tissues of Patients with Bronchial Asthma", Lancet, 2:11 (1982).
E. Frigas et al., "Cytotoxic Effects of the Guinea Pig Eosinophil Major Basic Protein on Tracheal Epithelium", Lab. Invest., 42:35 (1980).
E. Frigas et al., "Elevated Levels of The Eosinophil Granule Major Basic Protein in the Sputum of Patients with Bronchial Asthma", Mayo Clinic. Proc., 56:345 (1981).
T. Fujisawa et al., "Regulatory Effects of Cytokines on Eosinophil Degranulation", J. Immunol., 144:642 (1990).
G.J. Gleich, "Identification of a Major Basic Protein in Guinea Pig Eosinophil Granules", J. Exp. Med., 137:1459 (1973).
G.J. Gleich et al., "Cytotoxic Properties of the Eosinophil Major Basic Protein", J. Immunol., 123:2925 (1979).
G.J. Gleich et al., "The Eosinophilic Leukocyte: Structure and Function", Adv. Immunol., 39:177-253 (1986).
N.J. Gross et al., "Chapter 34: Anticholinergic Drugs", Allergy, Principles and Practice, vol. I, at pp. 782-808, E. Middleton Jr. et al., ed., The C.V. Mosby Company, publisher, (1988).
R.H. Gundel et al., "Repeated Antigen Inhalation Results in a Prolonged Airway Eosinophilia and Airway Eosinophilia and Airway Hyperresponsiveness in Primates", J. Appl. Physiol., 68:779 (1990).
Q. Hamid et al., "Expression of mRNA for Interleukin-5 in Mucosal Bronchial Biopsies from Asthma", J. Clin. Invest., 87:1541 (1991).
S.L. Harlin et al., "A Clinical and Pathologic Study of Chronic Sinusitis: The Role of the Eosinophil", J. Allergy Clin. Immunol., 81:867 (1988).
A.T. Hastie et al., "The Effect of Purified Human Eosinophil Major Basic Protein on Mammalian Ciliary Activity", Am. Rev. Resp. Dis., 135:845 (1987).
B.R. Horn et al., "Total Eosinophil Counts in the Management of Bronchial Asthma", N. Engl. J. Med., 292:1152 (1975).
M. Krasnowska et al., "A Test of Lidocaine Usage in the Treatment of Bronchial Asthma", Pneum. Pol., 50, pp. 269-273, (1982).
A.M. Lamas et al., "Glucocorticoids Specifically Decrease Eosinophil Survival", J. Allergy Clin. Immunol., 85:282, Abstract No. 554 (1990).
A.M. Lamas et al., "Glucocorticoids Specifically Decrease Eosinophil Survival", J. Immunol., 142:3978 (1989).
P.J. Mauser et al., "The Effect of Anti-Il-5 on Antigen-Induce Airway Hyperreactivity and Pulmonary Eosinophilia in Guinea Pigs", Am. Rev. Respir. Dis., 145:A859 (1992).
S. Motojimae t al., "Toxicity of Eosinophil Cationic Proteins for Guinea Pig Tracheal Epithelium in Vitro", Am. Rev. Resir. Dis., 139:801 (1989).
M.E. Rothenberg et al., "Human Eosinophil have Prolonged Survival, Enhanced Functional Properties, and Become Hypodense when Exposed to Human Interleukin 3", J. Clin. Invest., 81:1986 (1988).
V.N. Saperov, "The Treatment of Bronchial Asthma with the Aid of Intra-Arterial Injections of Novocain", Klin. Med., 45, pp. 50-54 (1967).
R.P. Schleimer et al., "Effects of Glucocorticosteroids on Inflammatory Cells Relevant to Their Therapeutic Applications in Asthma", Am. Rev. Respir. Dis., 141:559 (1990).
J.B. Sedgwich et al., "Immediate and Late Airway Response of Allergic Rhinitis Patients to Segmental Antigen Challenge", Am. Rev. Respir. Dis., 144:1274 (1991).
R. Sehmi et al., "Interleukin-5 Selectively Enhances the Chemotactics Response of Eosinophils Obtained from Normal but not Eosinophilic Subjects", Blood, 79:2952 (1992).
D.S. Silberstein et al., "Enhancement of Human Eosinophil Cytotoxicity and Leukotriene Synthesis by Biosynthetic (Recombinant) Granulocyte-Macrophage Colony-Stimulating Factor", J. Immunol., 137:3290 (1986).
D.S. Silberstein et al., "Hemopoietins for Eosinophils", Hematol. Oncol. Clin. North Am., 3:511 (1989).
S.D. Trocme et al., "Conjunctival Deposition of Eosinophil Granule Major Basic Protein in Vernal Keratoconjunctivitis and Contact Lens-Associated Giant Papillary Conjunctivitis", Am. J. Ophthamol., 108:57 (1989).
W.M. Tullett et al., Thorax, 37, 737 (1982).
I.J. Udell et al., "Eosinophil Granule Major Basic Protein and Charcot-Leyden Crystal Protein in Human Tears", Am. J. Ophthamol., 92:824 (1981).
T. Valerius et al., "Effects of IFN on Human Eosinophils in Comparison with Other Cytokines", J. Immunol., 145:2950 (1990).
N. Wallen et al., "Glucocorticoids Inhibit Cytokine-Mediated Eosinophil Survival", J. Immunol., 147:3940 (1991).
A.J. Wardlaw et al., "Eosinophils and Mast Cells in Bronchoalveolar Lavage in Subjects with Mild Asthma", Am. Rev. Resp. Dis., 137:62 (1988).
T.L. Wasmoen et al., "Biochemical and Amino Acid Sequence Analysis of Human Eosinophil Granule Major Basic Protein", J. Biol. Chem., 263:12559 (1988).
Merck Manual, pp. 622-627, (1982).
Remington's Pharmaceutical Sciences, pp. 1051-1052 (1985).
Gleich Gerald J.
Hunt Loren W.
Ohnishi Tsukasa
Henley III Raymond
Mayo Foundation for Medical Education & Research
LandOfFree
Method for the treatment of eosinophil-associated diseases by ad does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of eosinophil-associated diseases by ad, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of eosinophil-associated diseases by ad will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1724134